Key result
Potassium channel openers reduce major cardiovascular events, but clinical use remains limited by hypotension.
Why the study?
Potassium channel openers offer cardioprotective effects, prompting a critical evaluation of mechanistic and clinical evidence published between 2000 and 2024 on nicorandil and diazoxide in ischemia-reperfusion injury and cardiotoxicity.
Do potassium channel openers (nicorandil and diazoxide) reduce major adverse cardiovascular events and preserve mitochondrial integrity in ischemia-reperfusion injury and cardiotoxicity?
Do potassium channel openers (nicorandil and diazoxide) reduce major adverse cardiovascular events and preserve mitochondrial integrity in ischemia-reperfusion injury and cardiotoxicity?
Answers are grounded in this paper and cite their sources.
Potassium channel openers like nicorandil offer mitochondrial protection and MACE reduction in ischemia-reperfusion and cardiotoxicity, but require improved subtype selectivity and RCT validation to overcome dose-limiting hypotension.
Cardiovascular diseases remain a leading cause of global mortality. Potassium channel openers (PCOs) offer cardioprotective effects through modulation of cellular excitability and mitochondrial function. This narrative review critically evaluates mechanistic and clinical evidence published between 2000 and 2024, focusing on nicorandil and diazoxide in ischemia-reperfusion injury and cardiotoxicity. We examine mitochondrial ATP-sensitive potassium (mitoKATP) and large-conductance calcium-activated potassium (BKCa) channels, their roles in mitochondrial energetics and redox homeostasis, and their interplay with inhibition of mitochondrial permeability transition pore opening. Clinical contexts include cardioplegic arrest, myocardial infarction, and chemotherapy-induced cardiotoxicity. PCOs, particularly nicorandil, combine mitochondrial protection with hemodynamic benefits, with evidence supporting reductions in major adverse cardiovascular events and preservation of mitochondrial integrity. However, routine clinical integration remains constrained by translational gaps, inconsistent electrophysiological effects, and dose-limiting adverse events, including hypotension. Future development should prioritize mitochondrial channel subtype selectivity, particularly targeted mitoKATP and BKCa modulation, alongside well-designed randomized controlled trials to establish clinical efficacy and safety. These advances may strengthen the role of PCOs in cardiovascular medicine while minimizing systemic vascular adverse effects.
No takes yet. Share an insight, caveat, or question.
Shafiei et al. (2026) conducted a review in Cardiovascular diseases including ischemia-reperfusion injury, myocardial infarction, cardioplegic arrest, and chemotherapy-induced cardiotoxicity. Potassium channel openers (nicorandil, diazoxide) modulating mitoKATP and BKCa channels was evaluated on Major adverse cardiovascular events and preservation of mitochondrial integrity. Potassium channel openers, particularly nicorandil, show evidence supporting reductions in major adverse cardiovascular events, though clinical integration is constrained by hypotension.
Synapse has enriched 10 related papers. Consider them for comparative context: